Supplementary Figure S1. ERC-13-0234, revised

A

Lymph node metastasis (NRF2-positive cases)

Negative (n = 20)

Positive (n = 27)

free survival (%)

Disease

P = 0.014

Months after operation

0 20 40 60 80 100 120 140 160 180

B

Lymph node metastasis (NRF2-negative cases)

Negative (n = 35)

Positive (n = 24)

free survival (%)

Disease

P = 0.035

Months after operation

0 20 40 60 80 100 120 140 160 180

C

pT (NRF2-positive cases)

1 (n = 16)

2-4 (n = 31)

free survival (%)

Disease

P = 0.016

Months after operation

0 20 40 60 80 100 120 140 160 180

D

pT (NRF2-negative cases)

1 (n = 31)

2-4 (n = 29)

free survival (%)

Disease

P = 0.085

Months after operation

0 20 40 60 80 100 120 140 160 180

E

HER2 status (NRF2-positive cases)

Negative (n = 34)

Positive (n = 13)

free survival (%)

Disease

P = 0.044

Months after operation

0 20 40 60 80 100 120 140 160 180

F

HER2 status (NRF2-negative cases)

Negative (n = 51)

Positive (n = 8)

free survival (%)

Disease

P = 0.78

Months after operation

0 20 40 60 80 100 120 140 160 180
**G**

NQO1 status (NRF2-positive cases)

- Positive (n = 35)
- Negative (n = 12)

Free survival (%)

Disease

$P = 0.94$

Months after operation

**H**

NQO1 status (NRF2-negative cases)

- Negative (n = 45)
- Positive (n = 14)

Free survival (%)

Disease

$P = 0.64$

Months after operation